Abstract
New diagnostic or therapeutic options (NDTOs) are remunerated separately in the German DRG system. The Institute for Remuneration in Hospitals decides which proposed NDTOs are accepted for separate remuneration for 1 year. With this acceptance, hospitals can enter negotiations with insurance companies for an individual price of the NDTO. Because there are no general recommendations for these negotiations, we present a scheme for how to calculate an NDTO, based on the example of the NDTO for transurethral resection of bladder tumors using photodynamic diagnostic with hexaminolevulinic acid.
MeSH terms
-
Aminolevulinic Acid / analogs & derivatives*
-
Aminolevulinic Acid / economics
-
Biopsy / economics*
-
Budgets / organization & administration
-
Carcinoma, Transitional Cell / diagnosis
-
Carcinoma, Transitional Cell / economics
-
Carcinoma, Transitional Cell / pathology
-
Carcinoma, Transitional Cell / surgery
-
Cost-Benefit Analysis / legislation & jurisprudence
-
Cystoscopy / economics*
-
Diagnosis-Related Groups / economics*
-
Diagnosis-Related Groups / legislation & jurisprudence
-
Germany
-
Hospital Costs / legislation & jurisprudence*
-
Humans
-
Laser Therapy / economics*
-
Lasers, Solid-State / therapeutic use*
-
National Health Programs / economics*
-
National Health Programs / legislation & jurisprudence
-
Negotiating
-
Neoplasm Staging
-
Reimbursement Mechanisms / economics*
-
Reimbursement Mechanisms / legislation & jurisprudence
-
Technology, High-Cost / economics*
-
Technology, High-Cost / legislation & jurisprudence
-
Time and Motion Studies
-
Urinary Bladder Neoplasms / diagnosis
-
Urinary Bladder Neoplasms / economics*
-
Urinary Bladder Neoplasms / pathology
-
Urinary Bladder Neoplasms / surgery
Substances
-
Aminolevulinic Acid
-
5-aminolevulinic acid hexyl ester